Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €55.35 EUR
Change Today +0.05 / 0.09%
Volume 100.0
ABBV On Other Exchanges
Symbol
Exchange
EN Paris
Mexico
Frankfurt
As of 4:53 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1 North Waukegan Road

North Chicago, IL 60064

United States

Phone: 847-932-7900

Fax:

AbbVie Inc. operates as a research-based biopharmaceutical company worldwide. The company develops and markets advanced therapies that address various complex and serious diseases. The company’s products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson's disease; complications associated with chronic kidney disease and cystic fibrosis; and other health conditions, such as low testosterone. The company also has a pipeline of promising new medicines, including approximately 30 compounds or indications in Phase 2 or Phase 3 development across such important medical specialties as immunology, virology/liver disease, oncology, renal disease, neurological diseases, and women's health. Products HUMIRA HUMIRA is a biologic therapy administered as a subcutaneous injection. It is approved to treat various autoimmune diseases (rheumatoid arthritis (moderate to severe), psoriatic arthritis, ankylosing spondylitis, Crohn's disease (moderate to severe), plaque psoriasis (moderate to severe), juvenile idiopathic arthritis, ulcerative colitis (moderate to severe), axial spondyloarthropathy, pediatric Crohn's disease (severe), and pediatric enthesitis-related arthritis) in the United States, Canada, and Mexico (collectively, North America), as well as in the European Union. HUMIRA is also approved in approximately 60 other markets, including Japan, China, Brazil, and Australia. The company continues to dedicate research and development efforts to expanding indications for HUMIRA, including in the fields of rheumatology, gastroenterology (pediatric Crohn's disease and pediatric ulcerative colitis), dermatology (pediatric psoriasis and hidradenitis suppurativa), and ophthalmology (uveitis). Phase 3 trials are ongoing in preparation for regulatory applications for uveitis in the United States and the European Union. Regulatory applications for hidradenitis suppurativa have been filed in the United States and the European Union. The company continues to work on HUMIRA formulation and delivery improvements to improve convenience and the overall patient experience. HCV Products VIEKIRA PAK is an all-oral, short-course, interferon-free therapy, with or without ribavirin, for the treatment of adult patients with genotype 1 chronic HCV, including those with compensated cirrhosis. VIEKIRA PAK was approved by the U.S. Food and Drug Administration in December 2014. In Europe, the company’s HCV treatment is marketed as VIEKIRAX + EXVIERA and is approved for use in patients with genotype 1 and genotype 4 HCV. The European Commission granted marketing authorization for this treatment in January 2015. Additional Virology Products The company’s additional virology products include Kaletra and Norvir for the treatment of HIV infection and Synagis for the prevention of respiratory syncytial virus infection in high risk infants. Kaletra: Kaletra (also marketed as Aluvia in emerging markets) is a prescription anti-HIV-1 medicine that contains two protease inhibitors, such as lopinavir and ritonavir. Kaletra is used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1. Norvir: Norvir (ritonavir) is a protease inhibitor that is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Synagis: Synagis is a product marketed by the company outside of the United States that protects at-risk infants from severe respiratory disease caused by respiratory syncytial virus. Metabolics/Hormones Products Metabolic and hormone products target various conditions, including testosterone deficiency, exocrine pancreatic insufficiency, and hypothyroidism. These products comprise: AndroGel: AndroGel is a testosterone replacement therapy for males diagnosed with symptomatic low testosterone that is available in two strengths, such as 1 percent and 1.62 percent. Creon: Creon is a pancreatic enzyme therapy for exocrine pancreatic insufficiency, a condition that occur

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:FP €55.35 EUR +0.05

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.78 USD +0.28
Amgen Inc $162.59 USD 0.00
AstraZeneca PLC 4,727 GBp +40.50
Bristol-Myers Squibb Co $65.26 USD +0.26
Novo Nordisk A/S kr372.80 DKK +3.10
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings 52.6x
Price/Sales 4.6x
Price/Book 52.7x
Price/Cash Flow 51.7x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.